Does FAP CAR-Macrophage therapy alleviate myocardial ischemia-reperfusion injury?
FAP CAR-Macrophage therapy represents a novel proof-of-concept approach to alleviate myocardial ischemia-reperfusion injury and target fibrotic phenotypes.
Our proof-of-concept study demonstrates the therapeutic potential of FAP CAR-Ms in alleviating myocardial I/R and potentially opens new avenues for the treatment of a range of heart diseases that include a fibrotic phenotype.
Wang et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: